Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife, Inc. reported that one of its directors acquired additional common stock through a routine plan-related transaction. On 12/09/2025, the director obtained 687 shares of MetLife common stock at $77.82 per share, described as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director beneficially owns 102,754 shares of MetLife common stock in direct form.
A MetLife, Inc. director reported a small increase in holdings through automatic dividend reinvestment under the company’s Deferred Compensation Plan for Non-Management Directors. On 12/09/2025, the director acquired 11 shares of MetLife common stock at $77.82 per share via an imputed reinvestment of dividends on deferred shares. Following this transaction, the director beneficially owns 1,469 shares of MetLife common stock in direct form. The transaction was reported on a Form 4 as required for company insiders.
MetLife, Inc. director reports additional common stock from dividend reinvestment. On 12/09/2025, the director acquired 324 shares of MetLife common stock at $77.82 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. After this transaction, the director beneficially owned 44,776 shares directly and 10 shares indirectly through the MetLife Policyholder Trust, which holds stock allocated to eligible policyholders of Metropolitan Life Insurance Company.
MetLife, Inc. reported a small insider activity by one of its directors. On 12/09/2025, the director acquired 54 shares of MetLife common stock through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a price of $77.82 per share. Following this automatic dividend reinvestment, the director directly beneficially owns 7,425 shares of MetLife common stock.
MetLife, Inc. director reported a routine change in ownership of common stock linked to a compensation plan. On 12/09/2025, the director acquired 31 shares of MetLife common stock at $77.82 per share through imputed dividend reinvestment on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director directly beneficially owned 4,292 MetLife common shares. The filing notes that deferred shares are amounts that have become payable but that the director has chosen to defer receiving.
MetLife, Inc. filed a Form 4 reporting that one of its directors acquired additional common shares through an automatic dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors. On 12/09/2025, the director was credited with 166 shares of MetLife common stock at a price of $77.82 per share, described as imputed reinvestment of dividends on deferred shares. Following this transaction, the director beneficially owned 22,923 MetLife common shares in direct form.
MetLife, Inc. reported a small insider share acquisition by one of its directors. On 12/09/2025, the director acquired 34 shares of MetLife common stock at $77.82 per share, increasing the director’s beneficial ownership to 9,082 shares, held directly.
The transaction reflects imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Under this plan, directors can defer receipt of shares that have become payable, with dividends on those deferred shares reinvested in additional deferred share units.
MetLife, Inc. filed a current report to disclose that, on December 1, 2025, it completed its previously announced transaction with Talcott Resolution Life Insurance Company to reinsure approximately $10 billion of U.S. retail variable annuity and rider reserves. This means a large block of MetLife’s variable annuity risk has been transferred to Talcott through a reinsurance arrangement.
The completion of this transaction is communicated under a Regulation FD disclosure, with further details provided in a related news release that is attached as an exhibit and incorporated by reference.
MetLife-related accounts have filed a Form 144 to sell a small block of common stock. The notice covers a proposed sale of 335 shares of MetLife common stock through Wells Fargo, with an aggregate market value of 25,647.6, on the New York Stock Exchange on or about 12/01/2025. The issuer had 658,891,656 shares outstanding at the time referenced.
The seller acquired the 335 shares in a cash purchase from Goldman Sachs on 05/29/2015, with payment made on 06/03/2015. Over the past three months, several MetLife-related accounts, including Separate Account II, Separate Account SPI, Separate Account 149, the MetLife 401k Plan Trust-Large Cap Equity Index, and the MetLife 401k Plan Russell 1000 Value, sold additional blocks of MetLife common stock in multiple transactions, with gross proceeds for individual trades ranging from 1,345.72 to 27,282.69.
MetLife (MET) has a Form 144 notice covering a planned sale of common stock for the account of a reporting holder. The filing states that the holder intends to sell 30 shares of common stock through Barclays on the NYSE on or about 11/20/2025, with an aggregate market value of 2242.8. These 30 shares were acquired on 10/11/2021 via a purchase from Citigroup Global Markets, paid in cash on 10/13/2021.
The notice also lists other recent sales of the issuer’s common stock over the past three months by MetLife-related accounts, including 333 shares sold by MetLife 401k Plan Trust-Large Cap Equity Index on 10/01/2025 for gross proceeds of 27282.69 and 196 shares sold by MetLife 401k Plan Russell 1000 Value on 10/29/2025 for 15350.72. The signer represents that they are not aware of undisclosed material adverse information about the issuer.